MIRA Pharmaceuticals selects CHDR for Phase I/IIa trial of Ketamir-2; recruitment starts Q1 2025

MIRA PHARMACEUTICALS, INC.

Trial site: The Centre for Human Drug Research (CHDR) in Leiden, Netherlands.
Phase I in healthy subjects: initial safety/efficacy results expected H2 2025.
Phase IIa planned Q4 2025 in diabetic neuropathy patients; efficacy results in H1 2026.
Will use CHDR's PainCart® technology for early pain response measurement.
Psychoactivity assessed separately; trial leverages unique early-efficacy capability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.